Valor diagnóstico del pepsinógeno i/ii como biomarcador de lesiones pre-malignas y malignas gástricas: revisión sistemática
| Contribuinte(s) |
Isaza - Restrepo, Andrés Barragán González, Ana María |
|---|---|
| Data(s) |
30/11/2016
31/12/1969
|
| Resumo |
Antecedentes: El cáncer gástrico se diagnostica tardíamente. Sólo en países como Corea y Japón existen políticas de tamizaje, que se justificarían en cualquier país con alta prevalencia de cáncer gástrico como Colombia o Chile. El análisis del pepsinógeno sérico se ha propuesto para el diagnóstico de lesiones premalignas y malignas gástricas, por lo cual se pretende revisar sistemáticamente en la literatura el valor diagnóstico del cociente pepsinógeno I/II como marcador de lesiones premalignas y malignas gástricas. Metodología: Se revisó la literatura hasta septiembre del 2016 con palabras claves lesiones malignas, premalignas gástricas y pepsinógeno en las bases de datos PubMed, OVID, EMBASE, EBSCO, LILACS, OPENGRAY y Dialnet, artículos de prueba diagnóstica que evaluaran el cociente pepsinógeno I/II en relación con los hallazgos histológicos. Resultados: Se incluyeron 21 artículos conun total de 20601 pacientes, que demuestranuna sensibilidad entre13.7% - 91.2%, una especificidad entre 38.5% - 100%, un Valor Predictivo Positivo entre 6.3% - 100% y un Valor Predictivo Negativo entre 33.3% - 98.8%del cociente pepsinógeno I/II en relación con el diagnósticode lesiones premalignas y malignas gástricas. Conclusiones: Los valores del cociente pepsinógeno I/II disminuidos se relacionan con la presencia delesiones premalignas y malignas gástricas.Dado que tiene mejor especificidad que sensibilidad, en cuanto prueba para tamizaje, sería útil para la selección de pacientes que se beneficiaríande la EVDA. Se requieren más estudios de prueba diagnóstica para validar un punto de corte específico que pueda ser utilizado como valor estándar. Background: Gastric cancer is diagnosed late. Only in countries such as Koreaand Japan there are policies of screening, which would be justified in any country with a high prevalence of gastric cancer such as Colombia or Chile. The analysis of the serum pepsinogen had been proposed for the early diagnosis of premalignant and malignant lesions, the propose is to review systematically the literature the diagnostic value of the quotient pepsinogen I/II as a marker of gastric premalignant and malignant lesions. Methodology: we reviewed the literature until September 2016 with key words malignant and premalignant gastric lesions and pepsinogenin PubMed, OVID, EMBASE, EBSCO, LILACS, Dialnet and OPENGRAY, diagnostic test studies to evaluate the quotient pepsinogen I/II in relation to the histological findings. Results: 21 articles were included with a total of 20601 patients, with a sensitivity of 13.7% - 91.2%, a specificity of 38.5% - 100%, a positive predictive value of 6.3% - 100% and a negative predictive value of 33.3% - 98.8% of the quotient pepsinogen I/II in relation to the diagnosis of gastric premalignant and malignant lesions. Conclusions: The diminished values of the quotient pepsinogen I/II are related to the presence of premalignant and malignant gastric lesions. Given that the test has better specificity than sensitivity, for screening it would be useful for the selection of patients who would benefit from the UGE. More diagnostic test studies are required to validate acutoffpoint that can be used as the standard value. |
| Formato |
application/pdf |
| Identificador | |
| Idioma(s) |
spa |
| Publicador |
Facultad de Medicina |
| Direitos |
info:eu-repo/semantics/embargoedAccess |
| Fonte |
instname:Universidad del Rosario reponame:Repositorio Institucional EdocUR Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0 Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. International Agency for Research on Cancer. 2013 [cited 2014 Oct 20]. Ayala J, Lotero J. Tamización de cáncer gástrico. Univ Méd. 2013;54(2):209–22 Correa P, Piazuelo MB. Cáncer gástrico : el enigma colombiano. Rev Col Gastroenterol. 2010;25(4):334–7. World Health Organization (WHO). Colombia cancer profile [Internet]. Cancer country profiles. 2014 [cited 2014 Nov 20]. Petersen MP, Ramos CP, Garay ÓG, Suárez GH. Atlas de Mortalidad por Cáncer en Colombia. Instituto Nacional de Cancerología IGAC. Bogotá, Colombia: Imprenta Nacional; 2010. López H, Ospina J, Rubiano J, Rey M. Guía Clínica Cáncer Gástrico. Bogotá, Colombia: Asociación Colombiana de Cirugía de manejo en cirugía Cancer gástrico; 2009. Kuipers E, Klinkenberg-Knol E, Vandenbroucke-Grauls C, Appelmelk B, Schenk B, Meuwissen S. Role of Helicobacter pylori in the pathogenesis of atrophic gastritis. Scand J Gastroenterol. 1997;223:28–34. Regino WO. Cáncer gástrico en Colombia: un diagnóstico tardío que amerita el compromiso del Estado. Rev Colomb Gastroenterol. 2010;23:302–4. Inoue M, Tajima K, Matsuura A, Suzuki T, Nakamura T, Ohashi K, et al. Severity of chronic atrophic gastritis and subsequent gastric cancer occurrence: a 10-year prospective cohort study in Japan. Cancer Lett. 2000;161(1):105–12 Gritti I, Banfi G, Roi G. Pepsinogens : Physiology , Pharmacology Pathophysiology And Exercise. Pharmacol Res. 2000;41(3):265–81. Oliveros R, Albis R, Ceballos J, Ospina J, Villamizar J, Escobar J, et al. Evaluación de la concentración sérica de pepsinógeno como método de tamizaje para gastritis atrófica y cáncer. Rev Colomb Gastroentero. 2003;18(2):73–7 Yoshihara M, Hiyama T, Yoshida S, Ito M, Tanaka S, Watanabe Y, et al. Reduction in gastric cancer mortality by screening based on serum pepsinogen concentration: a case-control study. Scand J Gastroenterol. 2007;42(6):760–4. Catalano V, Labianca R, Beretta GD, Gatta G, de Braud F, Van Cutsem E. Gastric cancer. Crit Rev Oncol Hematol. 2009;71(2):127–64. Nagini S. Carcinoma of the stomach: A review of epidemiology, pathogenesis, molecular genetics and chemoprevention. World J Gastrointest Oncol. 2012;4(7):156–69. Lahner E, Bernardini G, Possenti S, Renzone G, Scaloni A, Santucci A, et al. Immunoproteomics of Helicobacter pylori infection in patients with atrophic body gastritis, a predisposing condition for gastric cancer. Int J Med Microbiol. Elsevier GmbH.; 2011;301(2):125–32. Aoki K, Kihaile PE, Wenyuan Z, Xianghang Z, Castro M, Disla M, et al. Comparison of prevalence of chronic atrophic gastritis in Japan, China, Tanzania, and the Dominican Republic. Ann Epidemiol. 2005;15(8):598–606. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. Gastric Cancer (including cancer in the proximal 5 cm of the stomach) [Internet].2013 [cited 2014 Nov 28]. Fernández J, De Aretxabala X, D Ricardo S, Sabah S, Jorge M, Navarro A, et al. Detección de lesiones preneoplásicas gástricas mediante niveles séricos de pepsinógeno en población chilena. Rev méd Chile. 2007;135(12):1519–25. Kang JM, Kim N, Yoo JY, Park YS, Lee DH, Kim HY, et al. The role of serum pepsinogen and gastrin test for the detection of gastric cancer in Korea. Helicobacter. 2008;13(2):146–56. Lomba-Viana R, Dinis-Ribeiro M, Fonseca F, Vieira AS, Bento MJB, Lomba-Viana H. Serum pepsinogen test for early detection of gastric cancer in a European Country. Eur J Gastroenterol Hepatol. 2012;24(1):37–41. Dinis-Ribeiro M, da Costa-Pereira A, Lopes C, Barbosa J, Guilherme M, Moreira-Dias L, et al. Validity of serum pepsinogen I/II ratio for the diagnosis of gastric epithelial dysplasia and intestinal metaplasia during the follow-up of patients at risk for intestinal-type gastric adenocarcinoma. Neoplasia. 2004;6(5):449–56. Zhang X-M, Li J-X, Zhang G-Y, Li X-H, Gu H. The value of serum pepsinogen levels for the diagnosis of gastric diseases in Chinese Han people in midsouth China. BMC Gastroenterol. 2014;14(1):3. Zhang X, Xue L, Xing L, Wang J, Cui J, Mi J, et al. Low serum pepsinogen I and pepsinogen I/II ratio and Helicobacter pylori infection are associated with increased risk of gastric cancer: 14-year follow up result in a rural Chinese community. Int J Cancer. 2012;130(7):1614–9. Chang YW, Hwangbo Y, Lee JW, Jo SJ, Cho JH, Shim J, et al. Clinical parameters including serum pepsinogen level and management strategy in patients with premalignant gastric dysplasia. Eur J Gastroenterol Hepatol. 2011 May;23(5):405–10. Chae H-D, Kim I-H, Lee GH, Shin I-H, Suh H-S, Jeon C-H. Gastric cancer detection using gastric juice pepsinogen and melanoma-associated gene RNA. Am J Clin Pathol. 2013;140(2):209–14. Iino C, Shimoyama T, Sasaki Y, Sawaya M, Hanabata N, Fukuda S. Influence of endoscopic submucosal dissection on serum levels of pepsinogens in patients with early gastric cancer. Dig Endosc. 2012;24(5):339–42. Agkoc M, Dursun H, Albayrak F, Yilmaz O, Kiziltunc A, Yilmaz A, et al. Usefulness of Serum Pepsinogen Levels as a Screening Test For Atrophic Gastritis and Gastric Cancer. Eurasian J Med. 2010;42(1):15–8. Martínez T. , et al. Niveles séricos de pepsinógeno y su capacidad diagnóstica de atrofia gástrica en diferentes poblaciones colombianas. Rev Colomb Cancerol. 2014;18(4):166-178. Huang YK, Yu JC, Kang WM, Ma ZQ, Ye X and Tian SB, Yan C. Significance of Serum Pepsinogens as a Biomarker for Gastric Cancer and Atrophic Gastritis Screening: A Systematic Review and Meta-Analysis. PLOS One. 2015 Nov 10;10(11):e0142080. Kitahara, F., Kobayashi, K., Sato, T., Kojima, Y., Araki, T., & Fujino, M. a. (1999). Accuracy of screening for gastric cancer using serum pepsinogen concentrations. Gut, 44(5), 693–7. Inoue, M., Tajima, K., Matsuura, A., Suzuki, T., Nakamura, T., Ohashi, K., Tominaga, S. (2000). Severity of chronic atrophic gastritis and subsequent gastric cancer occurrence: a 10-year prospective cohort study in Japan. Cancer Letters, 161(1), 105–112. Chae, H., Lee, J. H., Lim, J., Kim, M., Kim, Y., Han, K., Park, S. H. (2008). Clinical utility of serum pepsinogen levels as a screening test of atrophic gastritis. Korean Journal of Laboratory Medicine, 28(3), 201–206. Chung, H. W., Kim, J. W., Lee, J.-H., Song, S. Y., Chung, J. B., Kwon, O. H., & Lim, J.-B. (2009). Comparison of the validity of three biomarkers for gastric cancer screening: carcinoembryonic antigen, pepsinogens, and high sensitive C-reactive protein. Journal of Clinical Gastroenterology, 43(1), 19–26. Fernández, J., De Aretxabala, X., D Ricardo, S., Sabah, S., Jorge, M., Navarro, A.Reydet, I. (2007). Detección de lesiones preneoplásicas gástricas mediante niveles séricos de pepsinógeno en población chilena. Rev. Méd. Chile, 135(12), 1519–1525. Wu, Kai C., Li, H. T., Qiao, T. D., Li, C. N., Ji, W. S., Tian, F. Q. Fan, D. M. (2004). Diagnosis of atrophic body gastritis in Chinese patients by measuring serum pepsinogen. Chinese Journal of Digestive Diseases, 5(1), 22–27. Nardone, G., Rocco, A., Staibano, S., Mezza, E., Autiero, G., Compare, D. Budillon, G. (2005). Diagnostic accuracy of the serum profile of gastric mucosa in relation to histological and morphometric diagnosis of atrophy. Alimentary Pharmacology and Therapeutics, 22(11–12), 1139–1146. Shikata, K., Ninomiya, T., Yonemoto, K., Ikeda, F., Hata, J., Doi, Y., Kiyohara, Y. (2012). Optimal cutoff value of the serum pepsinogen level for prediction of gastric cancer incidence: the Hisayama Study. Scandinavian Journal of Gastroenterology, 47(6), 669–675. Ley, C., Mohar, A., Guarner, J., Herrera-goepfert, R., & Figueroa, L. S. (2001). Screening Markers for Chronic Atrophic Gastritis in Chiapas , Mexico Screening Markers for Chronic Atrophic Gastritis in Chiapas , Mexico 1. Cancer Epidemiology, Biomarkers & Prevention, 10 (February), 107–112. Kong, H., Hospital, F. A., Army, L., Hospital, G., General, G., & Healing, W. (2011). Original article, 124(15), 2260–2268. Shafaghi, A., Mansour-Ghanaei, F., Joukar, F., Sharafkhah, M., Mesbah, A., Askari, K., Rasoulian, J. (2013). Serum gastrin and the pepsinogen I/II ratio as markers for diagnosis of premalignant gastric lesions. Asian Pacific Journal of Cancer Prevention, 14(6), 3931–3936. Sun, L. P., Gong, Y. H., Wang, L., & Yuan, Y. (2007). Serum pepsinogen levels and their infiuencing factors: A population-based study in 6990 Chinese from North China. World Journal of Gastroenterology, 13(48), 6562–6567. Kim, E. H., Kang, H., Park, C. H., Choi, H. S., Jung, D. H., Chung, H., Lee, Y. C. (2015). The optimal serum pepsinogen cut-off value for predicting histologically confirmed atrophic gastritis. Digestive and Liver Disease, 47(8), 663–668. Kang, J. M., Kim, N., Yoo, J. Y., Park, Y. S., Lee, D. H., Kim, H. Y., Song, I. S. (2008). The role of serum pepsinogen and gastrin test for the detection of gastric cancer in Korea. Helicobacter, 13(2), 146–156. Miki, K. (2006). Gastric cancer screening using the serum pepsinogen test method. Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 9(4), 245–253. Leja, M., Kupcinskas, L., Funka, K., Sudraba, A., Jonaitis, L., Ivanauskas, A., Lin, J. T. (2009). The Validity of a Biomarker Method for Indirect Detection of Gastric Mucosal Atrophy Versus Standard Histopathology. Digestive Diseases and Sciences, 54(11), 2377–2384. Zhang, X.-M., Li, J.-X., Zhang, G.-Y., Li, X.-H., & Gu, H. (2014). The value of serum pepsinogen levels for the diagnosis of gastric diseases in Chinese Han people in midsouth China. BMC Gastroenterology, 14(1), 3. Sierra, R., Une, C., Ramirez, V., Gonzalez, M. I., Ramirez, J. A., De Mascarel. (2006). Association of serum pepsinogen with atrophic body gastritis in Costa Rica. Clinical and Experimental Medicine, 6(2), 72–78. Bae, S. E., Lee, J. H., Park, Y. S., Kim, S. O., Choi, J. Y., Ahn, J. Y., Jung, H.-Y. (2016). Decrease of serum total ghrelin in extensive atrophic gastritis: Comparison with pepsinogens in histological reference. Scandinavian Journal of Gastroenterology, 51(2), 137–144. Colarossi, A., Rocío, I., Prochazka, R., Reyes, U., Bussalleu, A., & Barúa, L. (2011). Pepsinógeno y Gastrina en el Diagnóstico no Invasivo, 31(2), 110–115. Inoue, M., Kobayashi, S., Matsuura, A., Hamajima, N., Tajima, K., & Tominaga, S. (1998). Agreement of endoscopic findings and serum pepsinogen levels as an indicator of atrophic gastritis. Cancer Epidemiology Biomarkers and Prevention, 7(3), 261–263. Yoshida, T., Kato, J., Inoue, I., Yoshimura, N., Deguchi, H., Mukoubayashi, C. Ichinose, M. (2014). Cancer development based on chronic active gastritis and resulting gastric atrophy as assessed by serum levels of pepsinogen and Helicobacter pylori antibody titer. International Journal of Cancer, 134(6), 1445–1457. Li, P., He, C., Sun, L., Dong, N., & Yuan, Y. (2013). Pepsinogen I and II expressions in situ and their correlations with serum pesignogen levels in gastric cancer and its precancerous disease. BMC Clinical Pathology, 13(1), 22. Bae, S. E., Lee, J. H., Park, Y. S., Kim, S. O., Choi, J. Y., Ahn, J. Y., Jung, H.-Y. (2016). Decrease of serum total ghrelin in extensive atrophic gastritis: Comparison with pepsinogens in histological reference. Scandinavian Journal of Gastroenterology, 51(2), 137–144. Hosseini, M., Amoueian, S., Attaranzadeh, A., Montazer, M., Soltani, G., Asadollahi, K., & Abangah, G. (2013). Serum gastrin 17, pepsinogen I and pepsinogen II in atrophic gastritis patients living in North-East of Iran. Journal of Research in Medical Sciences, 18(3), 225–229. TEME |
| Palavras-Chave | #616.994 #Pepsinógenos -- Diagnóstico #Neoplasias gástricas #Adecarcinoma #Adecarcinoma -- Estudio de casos #Gastric Cancer #Premalignant Gastric Lesions #Sistematic Review #Pepsinogen #Pepsinogen I/II Ratio |
| Tipo |
info:eu-repo/semantics/bachelorThesis info:eu-repo/semantics/acceptedVersion |
